Literature DB >> 21439441

Natural history of multiple sclerosis: early prognostic factors.

Ellen M Mowry1.   

Abstract

Multiple sclerosis is a heterogeneous disease, and predicting its course is difficult at the individual level. In this article, clinical, demographic, and additional features that are associated with the risk of relapses and of intermediate-term disability are reviewed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21439441     DOI： 10.1016/j.ncl.2011.01.001

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  11 in total

1.  Longitudinal changes in quality of life and related psychosocial variables in australians with multiple sclerosis.

Authors:  Judy Ann Wollin; Nancy Spencer; Elizabeth McDonald; Gary Fulcher; Maureen Bourne; Rex D Simmons
Journal:  Int J MS Care       Date:  2013

2.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Authors:  Amit Bar-Or; Ralf Gold; Ludwig Kappos; Douglas L Arnold; Gavin Giovannoni; Krzysztof Selmaj; John O'Gorman; Monica Stephan; Katherine T Dawson
Journal:  J Neurol       Date:  2013-09       Impact factor: 4.849

3.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Authors:  Michael Hutchinson; Robert J Fox; David H Miller; J Theodore Phillips; Mariko Kita; Eva Havrdova; John O'Gorman; Ray Zhang; Mark Novas; Vissia Viglietta; Katherine T Dawson
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

4.  Exploration of machine learning techniques in predicting multiple sclerosis disease course.

Authors:  Yijun Zhao; Brian C Healy; Dalia Rotstein; Charles R G Guttmann; Rohit Bakshi; Howard L Weiner; Carla E Brodley; Tanuja Chitnis
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

5.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

6.  Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.

Authors:  R Alroughani; J Al Hashel; S Lamdhade; S F Ahmed
Journal:  ISRN Neurol       Date:  2012-11-01

Review 7.  Current and future therapies for multiple sclerosis.

Authors:  Alireza Minagar
Journal:  Scientifica (Cairo)       Date:  2013-02-07

8.  Multiple sclerosis presents with psychotic symptoms and coexists with hypertrophic cardiomyopathy.

Authors:  Muhammed Emin Ozcan; Bahri Ince; Hasan Hüseyin Karadeli; Talip Asil
Journal:  Case Rep Neurol Med       Date:  2014-08-13

Review 9.  Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases.

Authors:  Marjana Brkic; Sriram Balusu; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

10.  Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

Authors:  Gavin Giovannoni; Per Soelberg Sorensen; Stuart Cook; Kottil W Rammohan; Peter Rieckmann; Giancarlo Comi; Fernando Dangond; Christine Hicking; Patrick Vermersch
Journal:  Mult Scler       Date:  2018-05-02       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.